June 28, 2017 09:49 AM EDT
Financing

Mer­sana scores a $75M IPO as Wall Street con­tin­ues to em­brace biotech

John Carroll

Editor & Founder

The mar­ket’s em­brace of new biotech list­ings is hold­ing strong.

Mer­sana Ther­a­peu­tics was the lat­est to cross the IPO line, rais­ing $75 mil­lion af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times